Yoshiaki Nakamura, MD, PhD, discusses the quantification threshold for tissue-free ctDNA in detecting residual tumor ...
ctDNA testing effectively stratifies Merkel cell carcinoma patients into high and low recurrence risk categories, influencing surveillance strategies. The study's cohorts revealed significant ...
The U.S. FDA recently approved the Itovebi-based regimen as a first-line treatment for people with HR+, Her2-negative breast ...
The studies will evaluate the use of circulating tumour DNA (ctDNA) in monitoring treatment response in breast cancer patients. The Precise MRD test is a genome sequencing (WGS) based test that ...
GlobalData on MSN27d
Myriad signs five partnerships to study MRD testing in breast cancerThe company plans to study the application of molecular residual disease (MRD) testing in breast cancer management using its ...
With newer breast cancer treatments, it’s essential that nurses and APPs educate themselves and advocate for their patients.
Revolutionary liquid biopsy offers non-invasive disease detection, monitoring, and personalized treatment, especially in ...
The symposium took place during the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain, with the ...
ctDNA, circulating tumor DNA ... a platform trial with adaptive randomization could become an efficient way to rapidly test interventions and biomarkers of sensitivity. Smaller sample sizes would be ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback